Life sciences company Complete Genomics Inc.'s stock was up nearly 10 percent in pre-market trading on Thursday. It closed up 44 percent the day before at $2.93 per share.
The Mountain View-based company's(NASDAQ:GNOM) stock boost was tied to an announcement about technology for whole genome sequencing that it says dramatically improves accuracy, enables fully-phased genomes, and reduces the amount of DNA required for testing.
Complete Genomics stock still is off from near $14 per share a year ago and its 52-week high of $15.60.
No comments:
Post a Comment